Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Noro, Rintaro ^a   Gemma, Akihiko ^a   Kosaihira, Seiji ^a   Kokubo, Yutaka ^a   Chen, Mingwei ^a   Seike, Masahiro ^a   Kataoka, Kiyoko ^a   Matsuda, Kuniko ^a   Okano, Tetsuya ^a   Minegishi, Yuji ^a   Yoshimura, Akinobu ^a   Kudoh, Shoji ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN;

ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIGANDS; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 33845660415     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-277     Document Type: Article

References (26)

1. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Dmitrovsky E: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53(10 Suppl):2379-85.
2. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
3. Ferry D, Hammond L, Ranson M, Kris MG, Miller V, Murray P, Tullo a, Feyereislova A, Rowinsky E: Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a Phase I study. Proc Am Soc Clin Oncol 2000, 19:3a. (abstract 5E)
4. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Averbuch S, Ochs J, Morris C, Feyereislova a, Swaisland H, Rowinsky EK: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20:2240-2250.
5. Thatcher N, Chang A, Parikh P, Pemberton K, Archer V: Results of a Phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. Proc Am Assoc Cancer Res 2005, 46:. (abstract. LB-6)
6. Bailey LR, Kris M, Wolf M, Kay A, Averbuch S, Askaa J, Janas M, Schmidt K, Fukuoka M: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer. IDEAL 1 and 2. Proc Am Assoc Cancer Res 2nd edition. 2003, 44:1362. (absract LB-170)
7. Lynch TJ, Bell DW, Sordella R, gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-39.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich h, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasald H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-500.
9. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M: Epidermal growth factor gene and protein and gefitinib sensitivity in non-small -cell lung cancer. J Natl Cancer Inst 2005, 97:643-55.
10. Araki J, Okamoto I, Suto R, Ichikawa Y, Sasaki J: Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung cancer 2005, 48:141-44.
11. Tanno S, Ohasaki Y, Nakanishi K, Toyoshima E, Kikuchi K: Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib("Iressa", ZD1839). Oncol Rep 2004, 12:1053-7.
12. Gemma A, Hagiwara K, Vincent F, Ke Y, Hancock AR, Nagashima M, Bennett WP, Harris CC: hSmad5 gene, a human hSmad family member: its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors. Oncogene 1998, 16:951-6.
13. Gemma A, Takenoshita S, Hagiwara K, Okamoto A, Spillare EA, McMemamin MG, Hussain SP, Forrester K, Zariwala M, Xiong Y, Harris CC: Molecular analysis of the cyclin-dependent kinase inhibitor genes p151NK4b/MTS2, p161NK4/MTS1, p18 and p19 in human cancer cell lines. Int J Cancer 1996, 68:605-11.
14. Mosmann T: Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
15. Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, Kudoh S: Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib(IRESSA). Br J cancer 2005, 92:1711-9.
16. Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, Hirohashi S: Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res 2001, 61:2751-8.
17. Hosoya Y, Gemma A, Seike M, Kurimoto F, Uematsu K, Hibino S, Yoshimura A, Shibuya M, Kudoh S: Alteration of the PTEN/ MMAC1 gene locus in primary lung cancer with distant metastasis. Lung Cancer 1999, 25:87-93.
18. Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ: Optimization of Patient Selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, k-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006, 12:2538-44.
19. Hirsch FR, Varella-Garcia M, NcCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J, Gandara DR, Southwest Oncology Group: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes;a Southwest Oncologu Group Study. J clin oncol 2005, 23:6838-45.
20. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-501.
21. Witta SE, Gemmill RM, Hirsh FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA Jr: Restoring E-cadherin expression increase sensitivity to epidermal growth factor inhibitor inhibitors in lung cancer cell lines. Cancer Res 2006, 66:944-50.
22. Sirotnak FM, Zakowski MF, Miller VA, Zakowski MF, Miller VA, Scher HI, Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000, 6:4885-92.
23. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH: ZD1839(Iressa);an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62:5749-54.
24. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004, 96:1133-41.
25. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagiawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005, 65:226-35.
26. Worthylake R, Opresko LK, Wiler HS: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both Erb-B2 and epidermal growth factor receptors. J Biol Chem 1999, 26:8865-74.